» Articles » PMID: 11404251

IL-12 Attenuates Bleomycin-induced Pulmonary Fibrosis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin (IL)-12 is a potent inducer of interferon (IFN)-gamma. We postulated that IL-12 would attenuate bleomycin-induced pulmonary fibrosis. To test this hypothesis, we administered IL-12 or murine serum albumin to bleomycin-treated mice by daily intraperitoneal injection until day 12. Mice treated with IL-12 demonstrated decreased hydroxyproline levels compared with control treated mice. Furthermore, administration of IL-12 led to a time-dependent increase in both lung and bronchoalveolar lavage fluid IFN-gamma. The antifibrotic effect of IL-12 could be attenuated with simultaneous administration of neutralizing anti-IFN-gamma antibodies. These findings support the notion that IL-12 attenuates bleomycin-induced pulmonary fibrosis via modulation of IFN-gamma production.

Citing Articles

Advances in understanding the role of interleukins in pulmonary fibrosis (Review).

He Y, Shen X, Zhai K, Nian S Exp Ther Med. 2024; 29(2):25.

PMID: 39650776 PMC: 11619568. DOI: 10.3892/etm.2024.12775.


Effectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study.

He X, Wang Y, Sun J, Li Y, Ruan G, Li Y Therap Adv Gastroenterol. 2024; 17:17562848241290663.

PMID: 39493260 PMC: 11528754. DOI: 10.1177/17562848241290663.


Non-Infectious Pneumonitis and Acute Respiratory Distress Syndrome in a Patient on Ustekinumab Treatment: Case Report and Literature Review.

Cioffi V, Di Napoli G, Tozzi P, Martelli S, Bruno K, Longo A Life (Basel). 2024; 14(3).

PMID: 38541718 PMC: 10971856. DOI: 10.3390/life14030394.


A meta-analysis of the clinical significance of neutrophil-to-lymphocyte ratios in interstitial lung disease.

Dong F, Zheng L, An W, Xue T, Zhong X PLoS One. 2023; 18(6):e0286956.

PMID: 37307262 PMC: 10259798. DOI: 10.1371/journal.pone.0286956.


Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?.

Thatcher T, Freeberg M, Myo Y, Sime P Pharmacol Ther. 2023; 247:108460.

PMID: 37244406 PMC: 10335230. DOI: 10.1016/j.pharmthera.2023.108460.